The EMA previously granted orphan designation to mavorixafor in WHIM syndrome. In April 2024, mavorixafor received U.S. Food and Drug Administration approval as XOLREMDI ®, an oral, once-daily ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback